MedWatch Safety Alerts

MedWatch Safety Alert RSS Feed

FDA MedWatch Safety Alerts

Evidence of NSAID toxicity in the pets exposed to flurbiprofen and died.
Posted: April 17, 2015, 4:15 pm
Separation could result in required intervention to prevent permanent impairment or damage.
Posted: April 16, 2015, 1:00 pm
Particles in IV solutions may cause: local vein irritation, inflammatory reaction, aggravation of preexisting infections, allergic reactions, and systemic embolization.
Posted: April 10, 2015, 2:40 pm
UPDATED 04/08/2015. Wallcur Practi-IV solutions bags are recalled.
Posted: April 8, 2015, 6:30 pm
Human and veterinary drug products made by the Prescription Center have been distributed nationwide and to Canada.
Posted: April 2, 2015, 3:45 pm
Risk of potentially life-threatening allergic reactions.
Posted: March 31, 2015, 11:00 am
If not properly reprocessed patients may be exposed to serious infections.
Posted: March 26, 2015, 7:00 pm
The facility may not perform mammography due to the revocation of its accreditation.
Posted: March 24, 2015, 7:10 pm
Postmarketing cases of serious and life-threatening symptomatic bradycardia, as well as one fatal cardiac arrest and cases requiring pacemaker insertion, have been reported.
Posted: March 24, 2015, 4:50 pm
FDA is unable to exclude the possibility that the deaths were caused by rapid, but delayed, entry of the drug into the bloodstream following intramuscular injection.
Posted: March 23, 2015, 6:00 pm
If asthma is not appropriately treated and managed, patients may be at risk for life-threatening asthma attacks.
Posted: March 19, 2015, 4:00 pm
Contaminated solution used on a patient may result in bacteremia, sepsis, septic shock and endocarditis, and death may result.
Posted: March 12, 2015, 11:30 am
Can lead to device failure, possible product contamination, and potential serious adverse health consequences.
Posted: March 11, 2015, 12:30 am
Rare risk of seizures, and studies of side effects on mood, behavior, or thinking. Posted 03/09/2015
Posted: March 9, 2015, 10:00 pm
Potential for delay in treatment of magnesium sulfate in 5% dextrose, that can result in life-threatening seizures, stroke, cerebral hemorrhage and maternal death, and attendant risks to the fetus, including fetal demise.
Posted: March 6, 2015, 7:10 pm
Risk of injury or death resulting from prolonged interruption in therapy.
Posted: March 6, 2015, 3:30 pm
Injected particulate material may result in localized inflammation, phlebitis, allergic reaction, granuloma formation or microembolic effects, and/or low-level allergic response.
Posted: March 6, 2015, 1:42 pm
UPDATED 3/4/2015. The Safety Communication has been updated. Updated Information for Healthcare Providers Regarding Duodenoscopes is provided.
Posted: March 4, 2015, 5:00 am
FDA requiring manufacturers to change labeling to clarify the approved uses of these medications, and to add information about a possible increased risk of heart attacks and strokes in patients taking testosterone.
Posted: March 3, 2015, 4:00 pm
Electrostatic discharge event could result in a pump stop, which could cause serious injury or death.
Posted: February 27, 2015, 3:40 pm